Generating Inhibitors of P-Glycoprotein: Where to, Now?

  • Emily Crowley
  • Christopher A. McDevitt
  • Richard Callaghan
Part of the Methods in Molecular Biology book series (MIMB, volume 596)


The prominent role for the drug efflux pump ABCB1 (P-glycoprotein) in mediating resistance to chemotherapy was first suggested in 1976 and sparked an incredible drive to restore the efficacy of anticancer drugs. Achieving this goal seemed inevitable in 1982 when a series of calcium channel blockers were demonstrated to restore the efficacy of chemotherapy agents. A large number of other compounds have since been demonstrated to restore chemotherapeutic sensitivity in cancer cells or tissues. Where do we stand almost three decades since the first reports of ABCB1 inhibition? Unfortunately, in the aftermath of extensive fundamental and clinical research efforts the situation remains gloomy. Only a small handful of compounds have reached late stage clinical trials and none are in routine clinical usage to circumvent chemoresistance. Why has the translation process been so ineffective? One factor is the multifactorial nature of drug resistance inherent to cancer tissues; ABCB1 is not the sole factor. However, expression of ABCB1 remains a significant negative prognostic indicator and is closely associated with poor response to chemotherapy in many cancer types. The main difficulties with restoration of sensitivity to chemotherapy reside with poor properties of the ABCB1 inhibitors: (1) low selectivity to ABCB1, (2) poor potency to inhibit ABCB1, (3) inherent toxicity and/or (4) adverse pharmacokinetic interactions with anticancer drugs. Despite these difficulties, there is a clear requirement for effective inhibitors and to date the strategies for generating such compounds have involved serendipity or simple chemical syntheses. This chapter outlines more sophisticated approaches making use of bioinformatics, combinatorial chemistry and structure informed drug design. Generating a new arsenal of potent and selective ABCB1 inhibitors offers the promise of restoring the efficacy of a key weapon in cancer treatment – chemotherapy.

Key words:

Multidrug resistance, ABC drug efflux pump, Combinatorial chemistry, Drug design, Pharmacophore modeling, Homology modeling High resolution structure Pharmacokinetic interactions 


  1. 1.
    Boyer J, Allen WL, McLean EG et al (2006) Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 66:2765–2777PubMedCrossRefGoogle Scholar
  2. 2.
    Cunningham L, Aplenc R (2007) Pharma­cogenetics of acute lymphoblastic leukemia treatment response. Expert Opin Pharma­cother 8:2519–2531PubMedCrossRefGoogle Scholar
  3. 3.
    Ferraldeschi R, Baka S, Jyoti B et al (2007) Modern management of small-cell lung cancer. Drugs 67:2135–2152PubMedCrossRefGoogle Scholar
  4. 4.
    Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1–22PubMedCrossRefGoogle Scholar
  5. 5.
    Longley DB, Allen WL, Johnston PG (2006) Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 1766:184–196PubMedGoogle Scholar
  6. 6.
    Surowiak P (2006) Prediction of the response to chemotherapy in ovarian cancers. Folia Morphol (Warsz) 65:285–294Google Scholar
  7. 7.
    Calzada MJ, del Peso L (2007) Hypoxia-inducible factors and cancer. Clin Transl Oncol 9:278–289PubMedCrossRefGoogle Scholar
  8. 8.
    Dang CV, Kim JW, Gao P, Yustein J (2008) The interplay between MYC and HIF in cancer. Nat Rev Cancer 8:51–56PubMedCrossRefGoogle Scholar
  9. 9.
    De Luca A, Carotenuto A, Rachiglio A et al (2008) The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214:559–567PubMedCrossRefGoogle Scholar
  10. 10.
    Fukumura D, Jain RK (2007) Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 74:72–84PubMedCrossRefGoogle Scholar
  11. 11.
    Tlsty TD, Coussens LM (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol 1:119–150PubMedCrossRefGoogle Scholar
  12. 12.
    Luqmani YA (2005) Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14(Suppl 1):35–48PubMedCrossRefGoogle Scholar
  13. 13.
    Mellor HR, Callaghan R (2008) Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 81:275–300PubMedCrossRefGoogle Scholar
  14. 14.
    Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340–7358PubMedCrossRefGoogle Scholar
  15. 15.
    Leonard GD, Fojo T, Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8:411–424PubMedCrossRefGoogle Scholar
  16. 16.
    Modok S, Mellor HR, Callaghan R (2006) Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6:350–354PubMedCrossRefGoogle Scholar
  17. 17.
    Ambudkar SV, Dey S, Hrycyna CA et al (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–398PubMedCrossRefGoogle Scholar
  18. 18.
    Callaghan R, Ford RC, Kerr ID (2006) The translocation mechanism of P-glycoprotein. FEBS Lett 580:1056–1063PubMedCrossRefGoogle Scholar
  19. 19.
    Pauwels EK, Erba P, Mariani G, Gomes CM (2007) Multidrug resistance in cancer: its mechanism and its modulation. Drug News Perspect. 20:371–377PubMedCrossRefGoogle Scholar
  20. 20.
    Cordon-Cardo C, O’Brien JP, Boccia J et al (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277–1287PubMedGoogle Scholar
  21. 21.
    Cordon-Cardo C, O’Brien JP, Casals D et al (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695–698PubMedCrossRefGoogle Scholar
  22. 22.
    Fromm MF (2003) Importance of P-glyco­protein for drug disposition in humans. Eur J Clin Invest 33(Suppl 2):6–9PubMedCrossRefGoogle Scholar
  23. 23.
    van der Valk P, van Kalken CK, Ketelaars H et al (1990) Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol 1:56–64PubMedGoogle Scholar
  24. 24.
    Callaghan R, Crowley E, Potter S, Kerr ID (2008) P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 48:365–378PubMedCrossRefGoogle Scholar
  25. 25.
    Burger H, van Tol H, Boersma AW et al (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104:2940–2942PubMedCrossRefGoogle Scholar
  26. 26.
    Chan HS, Grogan TM, Haddad G, DeBoer G, Ling V (1997) P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89:1706–1715PubMedCrossRefGoogle Scholar
  27. 27.
    Chan HS, Haddad G, Thorner PS et al (1991) P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608–1614PubMedCrossRefGoogle Scholar
  28. 28.
    van den Heuvel-Eibrink MM, Sonneveld P, Pieters R (2000) The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 38:94–110PubMedGoogle Scholar
  29. 29.
    Pallis M, Russell N (2004) Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia. Leukemia 18:1927–1930PubMedCrossRefGoogle Scholar
  30. 30.
    van der Holt B, Lowenberg B, Burnett AK et al (2005) The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106:2646–2654PubMedCrossRefGoogle Scholar
  31. 31.
    Donnenberg VS, Donnenberg AD (2005) Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45:872–877PubMedCrossRefGoogle Scholar
  32. 32.
    Merino V, Jimenez-Torres NV, Merino-Sanjuan M (2004) Relevance of multidrug resistance proteins on the clinical efficacy of cancer therapy. Curr Drug Deliv 1:203–212PubMedCrossRefGoogle Scholar
  33. 33.
    Ak I, Aslan V, Vardareli E, Gulbas Z (2003) Assessment of the P-glycoprotein expression by 99mTc-MIBI bone marrow imaging in patients with untreated leukaemia. Nucl Med Commun 24:397–402PubMedCrossRefGoogle Scholar
  34. 34.
    Jekerle V, Wang JH, Scollard DA et al (2006) 99mTc-Sestamibi, a sensitive probe for in vivo imaging of P-glycoprotein inhibition by modulators and mdr1 antisense oligodeoxynucleotides. Mol Imaging Biol 8:333–339PubMedCrossRefGoogle Scholar
  35. 35.
    Martin C, Berridge G, Mistry P et al (1999) The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128:403–411PubMedCrossRefGoogle Scholar
  36. 36.
    Pusztai L, Wagner P, Ibrahim N et al (2005) Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104:682–691PubMedCrossRefGoogle Scholar
  37. 37.
    Walker J, Martin C, Callaghan R (2004) Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 40:594–605PubMedCrossRefGoogle Scholar
  38. 38.
    Benson AB III, Trump DL, Koeller JM et al (1985) Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat Rep 69:795–799PubMedGoogle Scholar
  39. 39.
    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–1972PubMedGoogle Scholar
  40. 40.
    Tsuruo T, Iida H, Yamashiro M, Tsukagoshi S, Sakurai Y (1982) Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin. Biochem Pharm­acol 31:3138–3140PubMedCrossRefGoogle Scholar
  41. 41.
    Ganapathi R, Grabowski D (1983) Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res 43:3696–3699PubMedGoogle Scholar
  42. 42.
    Goldberg H, Ling V, Wong PY, Skorecki K (1988) Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 152:552–558PubMedCrossRefGoogle Scholar
  43. 43.
    Ramu A, Fuks Z, Gatt S, Glaubiger D (1984) Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate. Cancer Res 44:144–148PubMedGoogle Scholar
  44. 44.
    Tsuruo T, Iida H, Kitatani Y et al (1984) Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res 44:4303–4307PubMedGoogle Scholar
  45. 45.
    Bartlett NL, Lum BL, Fisher GA et al (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12:835–842PubMedGoogle Scholar
  46. 46.
    Berman E, McBride M, Lin S, Menedez-Botet C, Tong W (1995) Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia 9:1631–1637PubMedGoogle Scholar
  47. 47.
    Verweij J, Herweijer H, Oosterom R et al (1991) A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 64:361–364PubMedGoogle Scholar
  48. 48.
    Deferme S, Van Gelder J, Augustijns P (2002) Inhibitory effect of fruit extracts on P-glycoprotein-related efflux carriers: an in-vitro screening. J Pharm Pharmacol 54:1213–1219PubMedCrossRefGoogle Scholar
  49. 49.
    Ford JM, Prozialeck WC, Hait WN (1989) Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35:105–115PubMedGoogle Scholar
  50. 50.
    Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595–4602PubMedGoogle Scholar
  51. 51.
    Kane GC, Lipsky JJ (2000) Drug-grapefruit juice interactions. Mayo Clin Proc 75:933–942PubMedCrossRefGoogle Scholar
  52. 52.
    Newman MJ, Rodarte JC, Benbatoul KD et al (2000) Discovery and characterization of OC144–093, a novel inhibitor of P-glyco­protein-mediated multidrug resistance. Cancer Res 60:2964–2972PubMedGoogle Scholar
  53. 53.
    Nogae I, Kohno K, Kikuchi J et al (1989) Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein. Biochem Pharmacol 38:519–527PubMedCrossRefGoogle Scholar
  54. 54.
    Roe M, Folkes A, Ashworth P et al (1999) Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 9:595–600PubMedCrossRefGoogle Scholar
  55. 55.
    Sadzuka Y, Sugiyama T, Sonobe T (2000) Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance. Toxicol Lett 114:155–162PubMedCrossRefGoogle Scholar
  56. 56.
    Twentyman PR, Bleehen NM (1991) Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer 27:1639–1642PubMedCrossRefGoogle Scholar
  57. 57.
    Boniface GR, Ferry D, Atsmon J et al (2002) XR9576 (tariquidar), a potent and specific P-glycoprotein inhibitor, has minimal effects on the pharmacokinetics of paclitaxel, doxorubicin, and vinorelbine and can be administered with full-dose chemotherapy in patients with cancer. Proc Am Soc Clin Oncol 39:2173Google Scholar
  58. 58.
    Fox E, Bates SE (2007) Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 7:447–459PubMedCrossRefGoogle Scholar
  59. 59.
    Stewart A, Steiner J, Mellows G et al (2000) Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 6:4186–4191PubMedGoogle Scholar
  60. 60.
    Baer MR, George SL, Dodge RK et al (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100:1224–1232PubMedGoogle Scholar
  61. 61.
    Giaccone G, Linn SC, Welink J et al (1997) A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 3:2005–2015PubMedGoogle Scholar
  62. 62.
    Gruber A, Bjorkholm M, Brinch L et al (2003) A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Leuk Res 27:323–328PubMedCrossRefGoogle Scholar
  63. 63.
    Kamath AV, Chong S, Chang M, Marathe PH (2005) P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats. Cancer Chemother Pharmacol 55:110–116PubMedCrossRefGoogle Scholar
  64. 64.
    Kitazaki T, Oka M, Nakamura Y et al (2005) Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49:337–343PubMedCrossRefGoogle Scholar
  65. 65.
    Dawson RJ, Locher KP (2006) Structure of a bacterial multidrug ABC transporter. Nature 443:180–185PubMedCrossRefGoogle Scholar
  66. 66.
    Fischer E (1894) Einfluss der Configuration auf die Wirkung der Enzyme. Ber Dtsch Chem Ges 27:2985–2993CrossRefGoogle Scholar
  67. 67.
    McFarland BJ, Strong RK (2003) Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation. Immunity 19:803–812PubMedCrossRefGoogle Scholar
  68. 68.
    Koshland DE (1958) Application of a theory of enzyme specificity to protein synthesis. Proc Natl Acad Sci USA 44:98–104PubMedCrossRefGoogle Scholar
  69. 69.
    Sethi DK, Agarwal A, Manivel V, Rao KV, Salunke DM (2006) Differential epitope positioning within the germline antibody paratope enhances promiscuity in the primary immune response. Immunity 24:429–438PubMedCrossRefGoogle Scholar
  70. 70.
    Tamai I, Safa AR (1991) Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 266:16796–16800PubMedGoogle Scholar
  71. 71.
    Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV (1997) Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 94:10594–10599PubMedCrossRefGoogle Scholar
  72. 72.
    Ferry DR, Russell MA, Cullen MH (1992) P-glycoprotein possesses a 1, 4-dihydropyridine selective drug acceptor site which is allosterically coupled to a vinca alkaloid selective binding site. Biochem Biophys Res Commun 188:440–445PubMedCrossRefGoogle Scholar
  73. 73.
    Martin C, Berridge G, Higgins CF et al (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624–632PubMedGoogle Scholar
  74. 74.
    Orlowski S, Mir LM, Belehradek J, Garrigos M (1996) Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone and verapamil are mutually non-exclusive modulators. Biochem J 317:515–522PubMedGoogle Scholar
  75. 75.
    Pascaud C, Garrigos M, Orlowski S (1998) Multidrug resistance transporter P-glyco­protein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem J 333:351–358PubMedGoogle Scholar
  76. 76.
    Scala S, Akhmed N, Rao US et al (1997) P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol Pharmacol 51:1024–1033PubMedGoogle Scholar
  77. 77.
    Shapiro AB, Ling V (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250:130–137PubMedCrossRefGoogle Scholar
  78. 78.
    Lu L, Leonessa F, Clarke R, Wainer IW (2001) Competitive and allosteric interactions in ligand binding to P-glycoprotein as observed on an immobilized P-glycoprotein liquid chromatographic stationary phase. Mol Pharmacol 59:62–68PubMedGoogle Scholar
  79. 79.
    Martin C, Berridge G, Mistry P et al (2000) Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry 39:11901–11906PubMedCrossRefGoogle Scholar
  80. 80.
    Martin C, Higgins CF, Callaghan R (2001) The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein. Biochemistry 40: 15733–15742PubMedCrossRefGoogle Scholar
  81. 81.
    Wang EJ, Casciano CN, Clement RP, Johnson WW (2000) Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence. Biochim Biophys Acta 1481:63–74PubMedGoogle Scholar
  82. 82.
    Bruggemann EP, Germann UA, Gottesman MM, Pastan I (1989) Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine. J Biol Chem 264:15483–15488PubMedGoogle Scholar
  83. 83.
    Loo TW, Clarke DM (2002) Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J Biol Chem 277:44332–44338PubMedCrossRefGoogle Scholar
  84. 84.
    Pleban K, Kopp S, Csaszar E et al (2005) P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach. Mol Pharmacol 67:365–374PubMedCrossRefGoogle Scholar
  85. 85.
    Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162PubMedCrossRefGoogle Scholar
  86. 86.
    Stouch TR, Gudmundsson O (2002) Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev 54:315–328PubMedCrossRefGoogle Scholar
  87. 87.
    Raub TJ (2006) P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharmacol 3:3–25CrossRefGoogle Scholar
  88. 88.
    Cramer J, Kopp S, Bates SE, Chiba P, Ecker GF (2007) Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2. ChemMedChem 2:1783–1788PubMedCrossRefGoogle Scholar
  89. 89.
    Zamora JM, Pearce HL, Beck WT (1988) Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33:454–462PubMedGoogle Scholar
  90. 90.
    Pearce HL, Safa AR, Bach NJ et al (1989) Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci USA 86:5128–5132PubMedCrossRefGoogle Scholar
  91. 91.
    Ueda K, Okamura N, Hirai M et al (1992) Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267:24248–24252PubMedGoogle Scholar
  92. 92.
    Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517–2524PubMedCrossRefGoogle Scholar
  93. 93.
    Gottesman MM, Pastan I (1993) Bio­chemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427PubMedCrossRefGoogle Scholar
  94. 94.
    Bain LJ, McLachlan JB, LeBlanc GA (1997) Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. Environ Health Perspect 105:812–818PubMedCrossRefGoogle Scholar
  95. 95.
    Seelig A (1998) A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251:252–261PubMedCrossRefGoogle Scholar
  96. 96.
    Ecker G, Huber M, Schmid D, Chiba P (1999) The importance of a nitrogen atom in modulators of multidrug resistance. Mol Pharmacol 56:791–796PubMedGoogle Scholar
  97. 97.
    Martin YC, Kofron JL, Traphagen LM (2002) Do structurally similar molecules have similar biological activity? J Med Chem 45:4350–4358PubMedCrossRefGoogle Scholar
  98. 98.
    Cramer RD III, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959–5967CrossRefGoogle Scholar
  99. 99.
    Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130–4146PubMedCrossRefGoogle Scholar
  100. 100.
    Baroni M, Costantino G, Cruciani G et al (1993) Generating optimal linear PLS estimations (GOLPE): an advanced chemometric tool for handling 3D-QSAR problems. Quant Struct Act Relat 12:9–20CrossRefGoogle Scholar
  101. 101.
    Van Drie JH (2004) Pharmacophore discovery: a critical review. In: Bultinck P (ed) Computational medicinal chemistry for drug discovery. Marcel Dekker, New York, pp 437–460Google Scholar
  102. 102.
    Chang C, Swaan PW (2006) Computational approaches to modeling drug transporters. Eur J Pharm Sci 27:411–424PubMedCrossRefGoogle Scholar
  103. 103.
    Ekins S, Mestres J, Testa B (2007) In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol 152:21–37PubMedCrossRefGoogle Scholar
  104. 104.
    Bhat UG, Winter MA, Pearce HL, Beck WT (1995) A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Mol Pharmacol 48:682–689PubMedGoogle Scholar
  105. 105.
    Dhainaut A, Regnier G, Atassi G et al (1992) New triazine derivatives as potent modulators of multidrug resistance. J Med Chem 35:2481–2496PubMedCrossRefGoogle Scholar
  106. 106.
    Boote DJ, Dennis IF, Twentyman PR et al (1996) Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14:610–618PubMedGoogle Scholar
  107. 107.
    Rowinsky EK, Smith L, Wang YM et al (1998) Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 16:2964–2976PubMedGoogle Scholar
  108. 108.
    Stupp R, Bauer J, Pagani O et al (1998) Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Ann Oncol 9:1233–1242PubMedCrossRefGoogle Scholar
  109. 109.
    Kim RB, Wandel C, Leake B et al (1999) Interrelationship between substrates and inhi­bitors of human CYP3A and P-glycoprotein. Pharm Res 16:408–414PubMedCrossRefGoogle Scholar
  110. 110.
    Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129–134PubMedCrossRefGoogle Scholar
  111. 111.
    Erhlich P (1909) Current status of Chemotherapy Dtsch Chem Ges 42:17Google Scholar
  112. 112.
    van Drie JH (2003) Pharmacophore disco­very – lessons learned. Curr Pharm Des 9:1649–1664PubMedCrossRefGoogle Scholar
  113. 113.
    Martin YC, Bures MG, Danaher EA et al (1993) A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J Comput Aided Mol Des 7:83–102PubMedCrossRefGoogle Scholar
  114. 114.
    Jones G, Willett P, Glen RC (1995) A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. J Comput Aided Mol Des 9:532–549PubMedCrossRefGoogle Scholar
  115. 115.
    Clement OO, Mehl AT (2000) HipHop: pharmacophore based on multiple common-feature alignments. In: Guner OF (ed) Pharmacophore Perception, Development, and Use in Drug Design. IUL, San Diego, pp 69–84Google Scholar
  116. 116.
    Li H, Sutter J, Hoffman R (2000) HypoGen: an automated system for generating 3D predictive pharmacophore models. In: Guner OF (ed) Pharmacophore perception, development, and use in drug design. IUL, San Diego, pp 173–189Google Scholar
  117. 117.
    Ekins S, Kim RB, Leake BF et al (2002) Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 61:974–981PubMedCrossRefGoogle Scholar
  118. 118.
    Penzotti JE, Lamb ML, Evensen E, Grootenhuis PD (2002) A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem 45:1737–1740PubMedCrossRefGoogle Scholar
  119. 119.
    Rebitzer S, Annibali D, Kopp S et al (2003) In silico screening with benzofurane- and benzopyrane-type MDR-modulators. Farmaco 58:185–191PubMedCrossRefGoogle Scholar
  120. 120.
    Langer T, Eder M, Hoffmann RD, Chiba P, Ecker GF (2004) Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model. Arch Pharm (Weinheim) 337:317–327CrossRefGoogle Scholar
  121. 121.
    Pleban K, Kaiser D, Kopp S et al (2005) Targeting drug-efflux pumps – a pharmacoinformatic approach. Acta Biochim Pol 52:737–740PubMedGoogle Scholar
  122. 122.
    Bednarczyk D, Ekins S, Wikel JH, Wright SH (2003) Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol 63:489–498PubMedCrossRefGoogle Scholar
  123. 123.
    Chang C, Swaan PW, Ngo LY et al (2004) Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1. Mol Pharmacol 65:558–570PubMedCrossRefGoogle Scholar
  124. 124.
    Geldenhuys WJ, Malan SF, Murugesan T, Van der Schyf CJ, Bloomquist JR (2004) Synthesis and biological evaluation of pentacyclo[, 6).0(3, 10).0(5, 9)]undecane derivatives as potential therapeutic agents in Parkinson’s disease. Bioorg Med Chem 12:1799–1806PubMedCrossRefGoogle Scholar
  125. 125.
    Yates CR, Chang C, Kearbey JD et al (2003) Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res 20:1794–1803PubMedCrossRefGoogle Scholar
  126. 126.
    Pajeva IK, Wiese M (2002) Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). J Med Chem 45:5671–5686PubMedCrossRefGoogle Scholar
  127. 127.
    Garrigues A, Loiseau N, Delaforge M et al (2002) Characterization of two pharmacophores on the multidrug transporter P-glyco­protein. Mol Pharmacol 62: 1288–1298PubMedCrossRefGoogle Scholar
  128. 128.
    Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA (2002) Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther 301:427–434PubMedCrossRefGoogle Scholar
  129. 129.
    Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S (2006) Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 34:1976–1984PubMedCrossRefGoogle Scholar
  130. 130.
    Ecker GF, Stockner T, Chiba P (2008) Computational models for prediction of interactions with ABC-transporters. Drug Discov Today 13:311–317PubMedCrossRefGoogle Scholar
  131. 131.
    Slate DL, Bruno NA, Casey SM et al (1995) RS-33295-198: a novel, potent modulator of P-glycoprotein-mediated multidrug resistance. Anticancer Res 15:811–814PubMedGoogle Scholar
  132. 132.
    Kohler S, Stein WD (2003) Optimizing chemotherapy by measuring reversal of P-glycoprotein activity in plasma membrane vesicles. Biotechnol Bioeng 81:507–517PubMedCrossRefGoogle Scholar
  133. 133.
    Mistry P, Stewart AJ, Dangerfield W et al (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61:749–758PubMedGoogle Scholar
  134. 134.
    van Zuylen L, Sparreboom A, van der Gaast A et al (2000) The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacoki-netics of docetaxel. Clin Cancer Res 6:1365–1371PubMedGoogle Scholar
  135. 135.
    Fracasso PM, Goldstein LJ, de Alwis DP et al (2004) Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 10:7220–7228PubMedCrossRefGoogle Scholar
  136. 136.
    Le LH, Moore MJ, Siu LL et al (2005) Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol 56:154–160PubMedCrossRefGoogle Scholar
  137. 137.
    Chi KN, Chia SK, Dixon R et al (2005) A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs 23:311–315PubMedCrossRefGoogle Scholar
  138. 138.
    Higgins CF, Linton KJ (2004) The ATP switch model for ABC transporters. Nat Struct Mol Biol 11:918–926PubMedCrossRefGoogle Scholar
  139. 139.
    Sauna ZE, Ambudkar SV (2007) About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther 6:13–23PubMedCrossRefGoogle Scholar
  140. 140.
    Senior AE, Gadsby DC (1997) ATP hydrolysis cycles and mechanism in P-glycoprotein and CFTR. Semin Cancer Biol 8:143–150PubMedCrossRefGoogle Scholar
  141. 141.
    Boumendjel A, Di Pietro A, Dumontet C, Barron D (2002) Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev 22:512–529PubMedCrossRefGoogle Scholar
  142. 142.
    Conseil G, Baubichon-Cortay H, Dayan G et al (1998) Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 95:9831–9836PubMedCrossRefGoogle Scholar
  143. 143.
    Morris ME, Zhang S (2006) Flavonoid–drug interactions: effects of flavonoids on ABC transporters. Life Sci 78:2116–2130PubMedCrossRefGoogle Scholar
  144. 144.
    Harborne JB, Williams CA (2000) Advances in flavonoid research since 1992. Phyto­chemistry 55:481–504PubMedCrossRefGoogle Scholar
  145. 145.
    Castro AF, Altenberg GA (1997) Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem Pharmacol 53:89–93PubMedCrossRefGoogle Scholar
  146. 146.
    Jodoin J, Demeule M, Beliveau R (2002) Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 1542:149–159PubMedCrossRefGoogle Scholar
  147. 147.
    Zhang S, Morris ME (2003) Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304:1258–1267PubMedCrossRefGoogle Scholar
  148. 148.
    Cermak R (2008) Effect of dietary flavonoids on pathways involved in drug metabolism. Expert Opin Drug Metab Toxicol 4:17–35PubMedCrossRefGoogle Scholar
  149. 149.
    Moon YJ, Wang X, Morris ME (2006) Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 20:187–210PubMedCrossRefGoogle Scholar
  150. 150.
    von Itzstein M (2007) The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6:967–974CrossRefGoogle Scholar
  151. 151.
    Colman PM, Varghese JN, Laver WG (1983) Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41–44PubMedCrossRefGoogle Scholar
  152. 152.
    Varghese JN, Laver WG, Colman PM (1983) Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 303:35–40PubMedCrossRefGoogle Scholar
  153. 153.
    Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM (1992) The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14:327–332PubMedCrossRefGoogle Scholar
  154. 154.
    Goodford PJ (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28:849–857PubMedCrossRefGoogle Scholar
  155. 155.
    Gubareva LV, Webster RG, Hayden FG (2001) Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 45:3403–3408PubMedCrossRefGoogle Scholar
  156. 156.
    Smith BJ, McKimm-Breshkin JL, McDonald M et al (2002) Structural studies of the resistance of influenza virus neuramindase to inhibitors. J Med Chem 45:2207–2212PubMedCrossRefGoogle Scholar
  157. 157.
    Malaisree M, Rungrotmongkol T, Decha P et al (2008) Understanding of known drug–target interactions in the catalytic pocket of neuraminidase subtype N1. Proteins 71:1908–1918PubMedCrossRefGoogle Scholar
  158. 158.
    Cooper NJ, Sutton AJ, Abrams KR et al (2003) Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 326:1235PubMedCrossRefGoogle Scholar
  159. 159.
    Eiland LS, Eiland EH (2007) Zanamivir for the prevention of influenza in adults and children age 5 years and older. Ther Clin Risk Manag 3:461–465PubMedGoogle Scholar
  160. 160.
    McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ et al (1998) Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 72:2456–2462PubMedGoogle Scholar
  161. 161.
    Mendel DB, Tai CY, Escarpe PA et al (1998) Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42:640–646PubMedGoogle Scholar
  162. 162.
    Lee J-Y, Urbatsch IL, Senior AE, Wilkens S (2002) Projection structure of P-glycoprotein by electron microscopy. Evidence for a closed conformation of the nucleotide binding domains. J Biol Chem 277:40125–40131PubMedCrossRefGoogle Scholar
  163. 163.
    Lee J-Y, Urbatsch IL, Senior AE, Wilkens S (2008) Nucleotide-induced structural changes in p-glycoprotein observed by electron microscopy. J Biol Chem 283:5769–5779PubMedCrossRefGoogle Scholar
  164. 164.
    Rosenberg MF, Callaghan R, Ford RC, Higgins CF (1997) Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem 272:10685–10694PubMedCrossRefGoogle Scholar
  165. 165.
    Rosenberg MF, Callaghan R, Modok S, Higgins CF, Ford RC (2005) Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J Biol Chem 280:2857–2862PubMedCrossRefGoogle Scholar
  166. 166.
    Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, Ford RC (2003) Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 278:8294–8299PubMedCrossRefGoogle Scholar
  167. 167.
    Rosenberg MF, Velarde G, Ford RC et al (2001) Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J 20:5615–5625PubMedCrossRefGoogle Scholar
  168. 168.
    Locher KP, Lee AT, Rees DC (2002) The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science 296:1091–1098PubMedCrossRefGoogle Scholar
  169. 169.
    Pinkett HW, Lee AT, Lum P, Locher KP, Rees DC (2007) An inward-facing conformation of a putative metal-chelate-type ABC transporter. Science 315:373–377PubMedCrossRefGoogle Scholar
  170. 170.
    Hvorup RN, Goetz BA, Niederer M et al (2007) Asymmetry in the structure of the ABC transporter-binding protein complex BtuCD-BtuF. Science 317:1387–1390PubMedCrossRefGoogle Scholar
  171. 171.
    Hollenstein K, Dawson RJ, Locher KP (2007) Structure and mechanism of ABC transporter proteins. Curr Opin Struct Biol 17:412–418PubMedCrossRefGoogle Scholar
  172. 172.
    Oldham ML, Khare D, Quiocho FA, Davidson AL, Chen J (2007) Crystal structure of a catalytic intermediate of the maltose transporter. Nature 450:515–521PubMedCrossRefGoogle Scholar
  173. 173.
    Globisch C, Pajeva IK, Wiese M (2008) Identification of putative binding sites of P-glycoprotein based on its homology model. ChemMedChem 3:280–295PubMedCrossRefGoogle Scholar
  174. 174.
    Jones PM, George AM (2002) Mechanism of ABC transporters: a molecular dynamics simulation of a well characterized nucleotide-binding subunit. Proc Natl Acad Sci USA 99:12639–12644PubMedCrossRefGoogle Scholar
  175. 175.
    O’Mara ML, Tieleman DP (2007) P-glycoprotein models of the apo and ATP-bound states based on homology with Sav1866 and MalK. FEBS Lett 581:4217–4222PubMedCrossRefGoogle Scholar
  176. 176.
    Ravna AW, Sylte I, Sager G (2007) Molecular model of the outward facing state of the human P-glycoprotein (ABCB1), and comparison to a model of the human MRP5 (ABCC5). Theor Biol Med Model 4:33PubMedCrossRefGoogle Scholar
  177. 177.
    Stenham DR, Campbell JD, Sansom MS et al (2003) An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulfide cross-linking and homology modeling. FASEB J 17:2287–2289PubMedGoogle Scholar
  178. 178.
    Dawson RJ, Locher KP (2007) Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett 581:935–938PubMedCrossRefGoogle Scholar
  179. 179.
    Vandevuer S, Van Bambeke F, Tulkens PM, Prevost M (2006) Predicting the three-dimensional structure of human P-glycoprotein in absence of ATP by computational techniques embodying crosslinking data: insight into the mechanism of ligand migration and binding sites. Proteins 63:466–478PubMedCrossRefGoogle Scholar
  180. 180.
    Zolnerciks JK, Wooding C, Linton KJ (2007) Evidence for a Sav1866-like architecture for the human multidrug transporter P-glyco­protein. FASEB J 21:3937–3948PubMedCrossRefGoogle Scholar
  181. 181.
    Greenberger LM (1993) Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. J Biol Chem 268:11417–11425PubMedGoogle Scholar
  182. 182.
    Greenberger LM (1998) Identification of drug interaction sites in P-glycoprotein. Methods Enzymol 292:307–317PubMedCrossRefGoogle Scholar
  183. 183.
    Greenberger LM, Lisanti CJ, Silva JT, Horwitz SB (1991) Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded by mouse mdr1b. J Biol Chem 266:20744–20751PubMedGoogle Scholar
  184. 184.
    Taylor AM, Storm J, Soceneantu L et al (2001) Detailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wild-type protein. Br J Pharmacol 134:1609–1618PubMedCrossRefGoogle Scholar
  185. 185.
    Loo TW, Bartlett MC, Clarke DM (2006) Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. Biochem J 399:351–359PubMedCrossRefGoogle Scholar
  186. 186.
    Loo TW, Bartlett MC, Clarke DM (2006) Transmembrane segment 1 of human P-glyco­protein contributes to the drug-binding pocket. Biochem J 396:537–545PubMedCrossRefGoogle Scholar
  187. 187.
    Loo TW, Clarke DM (1997) Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate. J Biol Chem 272:31945–31948PubMedCrossRefGoogle Scholar
  188. 188.
    Loo TW, Clarke DM (1999) Identification of residues in the drug-binding domain of human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane. J Biol Chem 274:35388–35392PubMedCrossRefGoogle Scholar
  189. 189.
    Loo TW, Clarke DM (2000) Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane. J Biol Chem 275:39272–39278PubMedCrossRefGoogle Scholar
  190. 190.
    Loo TW, Clarke DM (2001) Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil. J Biol Chem 276:14972–14979PubMedCrossRefGoogle Scholar
  191. 191.
    Ecker GF, Csaszar E, Kopp S et al (2002) Identification of ligand-binding regions of P-glycoprotein by activated-pharmacophore photoaffinity labeling and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Mol Pharmacol 61: 637–648PubMedCrossRefGoogle Scholar
  192. 192.
    Loo TW, Clarke DM (2005) Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 206:173–185PubMedCrossRefGoogle Scholar
  193. 193.
    Loo TW, Clarke DM (1997) Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12. J Biol Chem 272: 20986–20989PubMedCrossRefGoogle Scholar
  194. 194.
    Loo TW, Clarke DM (2000) The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis. J Biol Chem 275:5253–5256PubMedCrossRefGoogle Scholar
  195. 195.
    Maki N, Hafkemeyer P, Dey S (2003) Allosteric modulation of human P-glyco­protein. Inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem 278:18132–18139PubMedCrossRefGoogle Scholar
  196. 196.
    Maki N, Dey S (2006) Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1). Biochem Pharmacol 72:145–155PubMedCrossRefGoogle Scholar
  197. 197.
    Maki N, Moitra K, Ghosh P, Dey S (2006) Allosteric modulation bypasses the requirement for ATP hydrolysis in regenerating low affinity transition state conformation of human P-glycoprotein. J Biol Chem 281:10769–10777PubMedCrossRefGoogle Scholar
  198. 198.
    Shapiro AB, Fox K, Lam P, Ling V (1999) Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 259:841–850PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Emily Crowley
    • 1
  • Christopher A. McDevitt
    • 1
  • Richard Callaghan
    • 1
  1. 1.Nuffield Department of Clinical Laboratory SciencesJohn Radcliffe Hospital, University of OxfordOxfordUK

Personalised recommendations